Norflex and Bacillus anthracis - a phase IV clinical study of FDA data
We study 1,832 people who take Norflex or have Bacillus anthracis. No report of Bacillus anthracis is found in people who take Norflex.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
No report is found.
What is Norflex?
Norflex has active ingredients of orphenadrine citrate. It is often used in muscle spasms. eHealthMe is studying from 1,832 Norflex users for its effectiveness, alternative drugs and more.
What is Bacillus Anthracis?
Bacillus anthracis: no further information found.
Do you take Norflex and have Bacillus anthracis?Check whether Bacillus anthracis is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Bacillus anthracis and when was it recovered:
Expand to all the drugs that have ingredients of orphenadrine citrate:
Alternative drugs to, pros and cons of Norflex:
- Norflex (1,832 reports)
Bacillus anthracis treatments and more:
COVID vaccines that are related to Bacillus anthracis:
- Bacillus anthracis in Moderna COVID Vaccine
- Bacillus anthracis in Pfizer BioNTech Covid Vaccine
- Bacillus anthracis in Johnson and Johnson Covid Vaccine
All the drugs that are associated with Bacillus anthracis:
All the conditions that are associated with Bacillus anthracis:
How the study uses the data?
The study uses data from the FDA. It is based on orphenadrine citrate (the active ingredients of Norflex) and Norflex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Fluconazole and Duodenal Polyp - now
- Entresto and Transferrin Saturation Decreased - now
- Loratadine and Fluphenazine Hydrochloride drug interaction - now
- Rytary and Mirtazapine drug interaction - a second ago
- Dexilant and Androgen Deficiency - 3 seconds ago
- Clindamycin Phosphate and Pelvic Inflammatory Disease - 3 seconds ago
- Vitamin D and Patanase drug interaction - 13 seconds ago
- Ammonium Chloride and Cardiac Disorder - 19 seconds ago
- Trintellix and Patanase drug interaction - 27 seconds ago
- Ezetimibe and Quetiapine Fumarate drug interaction - 27 seconds ago